Cargando…
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with the pathology, clinical characteristics and outcome. Materials and methods: Sev...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
e-Med
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392782/ https://www.ncbi.nlm.nih.gov/pubmed/22743083 http://dx.doi.org/10.1102/1470-7330.2012.0027 |
_version_ | 1782237644245172224 |
---|---|
author | Nishino, Mizuki Cryer, Sarah K. Okajima, Yuka Sholl, Lynette M. Hatabu, Hiroto Rabin, Michael S. Jackman, David M. Johnson, Bruce E. |
author_facet | Nishino, Mizuki Cryer, Sarah K. Okajima, Yuka Sholl, Lynette M. Hatabu, Hiroto Rabin, Michael S. Jackman, David M. Johnson, Bruce E. |
author_sort | Nishino, Mizuki |
collection | PubMed |
description | Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with the pathology, clinical characteristics and outcome. Materials and methods: Seventy-two patients with NSCLC treated with bevacizumab therapy were identified retrospectively. Baseline and follow-up chest computed tomography scan were reviewed to identify tumoral cavitation and subsequent filling in of cavitation. Radiographic cavitation patterns were classified into 3 groups. The clinical and outcome data were correlated with cavity formation and patterns. Results: Out of 72 patients, 14 patients developed cavitation after the initiation of bevacizumab therapy (19%; median time to event, 1.5 months; range 1.0–24.8 months). Three radiographic patterns of tumoral cavitation were noted: (1) development of cavity within the dominant lung tumor (n = 8); (2) development of non-dominant cavitary nodules (n = 3); and (3) development of non-dominant cavitary nodules with adjacent interstitial abnormalities (n = 3). Eleven patients (79%) demonstrated subsequent filling in of cavitation (the time from the cavity formation to filling in; median 3.7 months; range 1.9–22.7 months). No significant difference was observed in the clinical characteristics, including smoking history, or in the survival between patients who developed cavitation and those who did not. Smoking history demonstrated a significant difference across 3 radiographic cavitation patterns (P = 0.006). Hemoptysis was noted in 1 patient with cavity formation and 4 patients without, with no significant difference between the 2 groups. Conclusion: Tumoral cavitation occurred in 19% in patients with NSCLC treated with bevacizumab and demonstrated 3 radiographic patterns. Subsequent filling in of cavitation was noted in the majority of cases. |
format | Online Article Text |
id | pubmed-3392782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | e-Med |
record_format | MEDLINE/PubMed |
spelling | pubmed-33927822012-07-18 Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab Nishino, Mizuki Cryer, Sarah K. Okajima, Yuka Sholl, Lynette M. Hatabu, Hiroto Rabin, Michael S. Jackman, David M. Johnson, Bruce E. Cancer Imaging Original Article Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with the pathology, clinical characteristics and outcome. Materials and methods: Seventy-two patients with NSCLC treated with bevacizumab therapy were identified retrospectively. Baseline and follow-up chest computed tomography scan were reviewed to identify tumoral cavitation and subsequent filling in of cavitation. Radiographic cavitation patterns were classified into 3 groups. The clinical and outcome data were correlated with cavity formation and patterns. Results: Out of 72 patients, 14 patients developed cavitation after the initiation of bevacizumab therapy (19%; median time to event, 1.5 months; range 1.0–24.8 months). Three radiographic patterns of tumoral cavitation were noted: (1) development of cavity within the dominant lung tumor (n = 8); (2) development of non-dominant cavitary nodules (n = 3); and (3) development of non-dominant cavitary nodules with adjacent interstitial abnormalities (n = 3). Eleven patients (79%) demonstrated subsequent filling in of cavitation (the time from the cavity formation to filling in; median 3.7 months; range 1.9–22.7 months). No significant difference was observed in the clinical characteristics, including smoking history, or in the survival between patients who developed cavitation and those who did not. Smoking history demonstrated a significant difference across 3 radiographic cavitation patterns (P = 0.006). Hemoptysis was noted in 1 patient with cavity formation and 4 patients without, with no significant difference between the 2 groups. Conclusion: Tumoral cavitation occurred in 19% in patients with NSCLC treated with bevacizumab and demonstrated 3 radiographic patterns. Subsequent filling in of cavitation was noted in the majority of cases. e-Med 2012-05-25 /pmc/articles/PMC3392782/ /pubmed/22743083 http://dx.doi.org/10.1102/1470-7330.2012.0027 Text en © 2012 International Cancer Imaging Society |
spellingShingle | Original Article Nishino, Mizuki Cryer, Sarah K. Okajima, Yuka Sholl, Lynette M. Hatabu, Hiroto Rabin, Michael S. Jackman, David M. Johnson, Bruce E. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab |
title | Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab |
title_full | Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab |
title_fullStr | Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab |
title_full_unstemmed | Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab |
title_short | Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab |
title_sort | tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392782/ https://www.ncbi.nlm.nih.gov/pubmed/22743083 http://dx.doi.org/10.1102/1470-7330.2012.0027 |
work_keys_str_mv | AT nishinomizuki tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab AT cryersarahk tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab AT okajimayuka tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab AT sholllynettem tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab AT hatabuhiroto tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab AT rabinmichaels tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab AT jackmandavidm tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab AT johnsonbrucee tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab |